Compare WFRD & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFRD | BLCO |
|---|---|---|
| Founded | 1941 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.0B |
| IPO Year | 2014 | 2022 |
| Metric | WFRD | BLCO |
|---|---|---|
| Price | $96.22 | $17.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $93.25 | $18.55 |
| AVG Volume (30 Days) | ★ 1.0M | 452.4K |
| Earning Date | 05-04-2026 | 05-21-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.93 | N/A |
| Revenue | $4,331,000,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $0.37 | $7.45 |
| Revenue Next Year | $3.48 | $5.49 |
| P/E Ratio | $16.40 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $36.74 | $10.45 |
| 52 Week High | $110.57 | $18.92 |
| Indicator | WFRD | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 56.53 |
| Support Level | $68.68 | $16.35 |
| Resistance Level | $106.38 | $18.92 |
| Average True Range (ATR) | 3.58 | 0.64 |
| MACD | -1.44 | 0.03 |
| Stochastic Oscillator | 8.13 | 64.91 |
Weatherford provides oilfield services and equipment to national, integrated, public, and private oil and gas operators. It operates across multiple upstream markets, including offshore, the rest of the world onshore, and US onshore, where Weatherford has limited exposure. The Middle East, North Africa, and Asia account for over 25% of sales. Weatherford also offers manufacturing, research, and training services. Performance is reported through three segments: drilling and evaluation, well construction and completions, and production and intervention.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.